What Makes Journey Medical Corporation (DERM) a Good Investment?

2 days ago 3

Soumya Eswaran

Wed, November 19, 2025 astatine 7:18 AM CST 3 min read

Summers Value Partners, an concern absorption company, released its third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Summers Value Fund LP returned a nett instrumentality of 20.4% nett successful Q3 2025, surpassing the 12.4% instrumentality of the Russell 2000 Index ETF (IWM) and the 12.5% instrumentality for the Russell 2000 Value Index ETF (IWN). Year-to-date, the money is up 4.9% nett compared to 10.3% and 8.9% returns for the indexes, respectively. In addition, you tin cheque the fund’s apical 5 holdings to find retired its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Summers Value Partners highlighted stocks specified arsenic Journey Medical Corporation (NASDAQ:DERM). Journey Medical Corporation (NASDAQ:DERM) engages successful the improvement and commercialization of pharmaceutical products for the attraction of dermatological conditions. The one-month instrumentality of Journey Medical Corporation (NASDAQ:DERM) was 8.46%, and its shares gained 52.01% of their worth implicit the past 52 weeks. On November 18, 2025, Journey Medical Corporation (NASDAQ:DERM) banal closed astatine $7.95 per share, with a marketplace capitalization of $215.73 million.

Summers Value Partners stated the pursuing regarding Journey Medical Corporation (NASDAQ:DERM) successful its 3rd 4th 2025 capitalist letter:

"Journey Medical develops and markets dermatology products. The institution precocious launched Emrosi for the attraction of rosacea. The rollout continues to beryllium connected track, with annualized income approaching $30 cardinal successful the archetypal six months pursuing its launch. We judge Emrosi could transcend $100 cardinal successful highest income based connected affirmative doc and diligent feedback. The institution is positioned for profitability successful 2026, supported by a scalable concern model. Given ongoing consolidation successful the dermatology industry, Journey whitethorn besides beryllium viewed arsenic an charismatic acquisition candidate. Our terms people remains $20 per share."

Journey Medical Corporation (NASDAQ:DERM) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 4 hedge money portfolios held Journey Medical Corporation (NASDAQ:DERM) astatine the extremity of the 2nd quarter, compared to 6 successful the erstwhile quarter. Journey Medical Corporation’s (NASDAQ:DERM) revenue for the 3rd 4th of 2025 was $17.6 cardinal compared to $14.9 cardinal successful Q3 2024. While we admit the imaginable of Journey Medical Corporation (NASDAQ:DERM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.